-
公开(公告)号：US08242106B2
公开(公告)日：2012-08-14
申请号：US12533596
申请日：2009-07-31
IPC分类号： A61K31/55 , C07D223/16
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：US09216192B2
公开(公告)日：2015-12-22
申请号：US13550192
申请日：2012-07-16
IPC分类号： C07D223/16 , C07D227/10 , A61K31/55 , A61K31/724 , A61K9/00 , A61K9/08 , A61K9/19 , A61K47/48 , B82Y5/00 , C08B37/16
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：US20130018042A1
公开(公告)日：2013-01-17
申请号：US13550192
申请日：2012-07-16
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：US20100029585A1
公开(公告)日：2010-02-04
申请号：US12533596
申请日：2009-07-31
IPC分类号： A61K31/724 , A61P35/00
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
